You are here

Study: Renal Denervation Doesn’t Lower Blood Pressure

About 10,000 procedures have been performed worldwide

Renal denervation — an experimental therapy that was once hailed as a possible cure for patients whose hypertension does not respond to medication — has been shown to be ineffective, according to a new study published in the New England Journal of Medicine.

The treatment has been approved for use in 80 countries but is still considered experimental in the U.S. An estimated 10,000 procedures have been performed worldwide.

In a prospective, single-blind, randomized, sham-controlled trial, 535 patients with severe, resistant hypertension were randomly assigned to undergo renal denervation or a sham procedure. Before randomization, the patients were treated with a stable antihypertensive regimen involving maximally tolerated doses of at least three drugs, including a diuretic.

The study’s primary efficacy endpoint was the change in office systolic blood pressure (SBP) at 6 months. A secondary efficacy endpoint was the change in mean 24-hour ambulatory SBP. The primary safety endpoint was a composite of death, end-stage renal disease, embolic events resulting in end-organ damage, renovascular complications, or hypertensive crisis at 1 month or new renal-artery stenosis of more than 70% at 6 months.

At 6 months, the mean change in SBP was –14.13 mm Hg in the denervation group compared with –11.74 mm Hg in the sham-procedure group (P P = 0.26 for superiority). The change in 24-hour ambulatory SBP was –6.75 mm Hg in the denervation group and –4.79 mm Hg in the sham-procedure group, for a difference of –1.96 mm Hg (P = 0.98 for superiority).

There were no significant differences in safety between the two groups.

The authors concluded that their study did not show a significant reduction of SBP in patients with resistant hypertension 6 months after renal-artery denervation compared with a sham control.

Sources: Medical Xpress; March 29, 2014; and NEJM; March 29, 2014.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs